Table 1 Patient characteristics
Clinical | Â |
|---|---|
   Female, n | 145 (49%) |
   Age, years (SD) | 58 (11) |
   Median duration of diabetes, months (IQR) | 72 (36, 120) |
   History of hypertension, n | 175 (60%) |
   History of dyslipidaemia, n | 206 (70%) |
   Body mass index, kg/m2 (SD) | 31.9 (7.0) |
   Systolic blood pressure, mmHg (SD) | 134 (18) |
   Diastolic blood pressure, mmHg (SD) | 81 (11) |
   HbA1c, % (SD) | 7.3 (1.5) |
   Median UACR, mg/mmol (IQR) | 1.2 (0.4, 4.0) |
   Normal UACR (<2.5 mg/mmol), n | 189 (66%) |
   Microalbuminuria (UACR 2.5 - 20 mg/mmol), n | 72 (25%) |
   Macroalbuminuria (UACR ≥20 mg/mmol), n | 27 (9%) |
Current therapy | Â |
   Oral hypoglycaemic therapy, n | 269 (91%) |
   Subcutaneous insulin therapy, n | 31 (11%) |
   Any antihypertensive therapy, n | 190 (65%) |
   Statin therapy, n | 178 (61%) |
Echocardiographic characteristics | Â |
   Left ventricular mass, g (SD) | 207 (63) |
   Left ventricular mass index, g/m2.7 (SD) | 51.5 (14.6) |
   Left ventricular hypertrophy, n | 164 (56%) |
Mild, n | 52 (18%) |
Moderate, n | 49 (17%) |
Severe, n | 63 (21%) |
   Regional wall motion abnormality, n | 17 (6%) |
   Left ventricular systolic dysfunction, n | 12 (4%) |
   Left ventricular diastolic dysfunction, n | 260 (89%) |
Abnormal relaxation, n | 173 (59%) |
Pseudonormal filling, n | 87 (30%) |